Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014598 | 0.88 | ROCK1 (0.53) | FFAR4ROCK1L3MBTL1MAPTMAPK1 | |
| SCHEMBL12151310 | 0.85 | FFAR4 (0.46) | FFAR4ROCK1KDM1AMAOAMAOB | |
| SCHEMBL30234345 | 0.85 | ROCK1 (0.57) | FFAR4ROCK1L3MBTL1MAPTMAPK1 | |
| SCHEMBL23883404 | 0.85 | ROCK1 (0.57) | FFAR4ROCK1L3MBTL1MAPTMAPK1 | |
| SCHEMBL2835447 | 0.81 | ROCK1 (0.53) | FFAR4ROCK1L3MBTL1MAPTMAPK1 | |
| SCHEMBL2837205 | 0.80 | ROCK1 (0.57) | ROCK1L3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL1728482 | 0.79 | S1PR5 (0.39) | FFAR4ROCK1MAPTMRGPRX4KDM1A | |
| SCHEMBL2007484 | 0.79 | MAPK14 (0.41) | FFAR4ROCK1L3MBTL1MAPTMAPK1 | |
| SCHEMBL1014177 | 0.78 | ROCK1 (0.43) | FFAR4ROCK1MRGPRX4KDM1ASLC6A4 | |
| SCHEMBL2833827 | 0.77 | ROCK1 (0.54) | ROCK1L3MBTL1MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012009617-A3 | METHODS, STORAGE MEDIUMS, AND SYSTEMS FOR ANALYZING PARTICLE QUANTITY AND DISTRIBUTION WITHIN AN IMAGING REGION OF AN ASSAY ANALYSIS SYSTEM AND FOR EVALUATING THE PERFORMANCE OF A FOCUSING ROUTING PERFORMED ON AN ASSAY ANALYSIS SYSTEM | LUMINEX CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2271617-B1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LTD (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| EP-2271617-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103710-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103710-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324106-A1 | COMPOUNDS | ESR2, GPER1, ESR1 | FFAR4 244/4885ROCK1 1875/4885L3MBTL1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.